MiNK Therapeutics Q2 FY26 net loss narrows to $3.13 million; cash falls to $8.81 million - INKT News | RalliesMiNK Therapeutics Q2 FY26 net loss narrows to $3.13 million; cash falls to $8.81 million
I
INKT• Clinical trial update
- The randomized Phase 2 C-1300-02 trial in acute lung injury was initiated in May.
- Initial Day 28 observations showed survival and improved oxygenation.
Q2 results and cash position
- MiNK Therapeutics posted a Q2 net loss of $3.13 million, narrowing from $4.24 million a year earlier.
- Loss per share improved to $0.62 from $1.06 in the prior-year quarter.
- Cash and cash equivalents fell to $8.81 million at June 30 from $13.36 million at Dec. 31.
- Cash used in operations rose to $2.08 million from $1.57 million a year earlier.
